Outcomes in NSCLC Patients with EGFR Co-Mutations Receiving Aumolertinib as First-Line Treatment: the Updated Results

被引：0
|
作者：
Fang, S. [1 ]
Xu, T. [1 ]
Liu, N. [1 ]
Wang, X. Y. [1 ]
Cheng, W. W. [1 ]
Fang, H. H. [1 ]
机构：
[1] Nanjing Chest Hosp, Affiliated Brain Hosp Nanjing Med Univ, Nanjing, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 11期
关键词：
aumolertinib; non-small-cell lung cancer; co-mutations;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP12.01-25
引用
收藏
页码：S650 / S650
页数：1
相关论文
共 50 条
  • [41] Treatment of NSCLC Patients with Malignant Pleural Effusion Harboring Exon 19 and 21 EGFR Mutations after First-Line and Second-Line TKIs
    Zheng, Zhen
    Jin, Xiance
    Xie, Congying
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1245 - S1246
  • [42] Furmonertinib Plus Icotinib as First-Line Treatment in EGFR-Mutated NSCLC: Updated Results in L858R and CNS Metastases Groups
    Chen, H.
    Huang, G.
    Xia, T.
    Chen, R.
    Lin, M.
    Yang, D.
    Luo, Y.
    Chen, H.
    Yang, Z.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S348 - S348
  • [43] Clinical implications of ctDNA for EGFR-TKIs as first-line treatment in NSCLC
    Xiao Liang
    Wei Zhang
    Jun Li
    Jing Zhu
    Jun Shao
    Jing Wang
    Hongshuai Wu
    Jiali Dai
    Jun Li
    Jiali Xu
    Wei Wang
    Renhua Guo
    Journal of Cancer Research and Clinical Oncology, 2023, 149 : 1211 - 1220
  • [44] Clinical characteristics of KRAS mutations in NSCLC and their impact on outcomes to first-line chemotherapy
    Butaney, Mohit
    Porter, Jennifer
    Lindeman, Neal Ian
    Janne, Pasi A.
    Rabin, Michael S.
    Marcoux, J. Paul
    Johnson, Bruce E.
    Jackman, David Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [45] Clinical implications of ctDNA for EGFR-TKIs as first-line treatment in NSCLC
    Liang, Xiao
    Zhang, Wei
    Li, Jun
    Zhu, Jing
    Shao, Jun
    Wang, Jing
    Wu, Hongshuai
    Dai, Jiali
    Xu, Jiali
    Wang, Wei
    Guo, Renhua
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (03) : 1211 - 1220
  • [46] Bevacizumab in EGFR-positive NSCLC: time to change first-line treatment?
    Yang, James Chih-Hsin
    LANCET ONCOLOGY, 2019, 20 (05): : 602 - 603
  • [47] Impact of Baseline Clinical Biomarkers on Treatment Outcomes in Patients With Advanced NSCLC Receiving First-line Pembrolizumab-Based Therapy
    Joshi, Ishani
    Peravali, Monica
    Geng, Xue
    Rao, Suman
    Chen, Kevin Y.
    Veytsman, Irina
    Giaccone, Giuseppe
    Liu, Stephen, V
    Kim, Chul
    CLINICAL LUNG CANCER, 2022, 23 (05) : 438 - 445
  • [48] Conversion to Aumolertinib in NSCLC Patients with EGFR Mutations Who Are Safety Intolerant after Osimertinib Treatment: A Retrospective Study
    Yao, B.
    Yang, L. F.
    Ran, T.
    Deng, S.
    Xu, Q.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S666 - S667
  • [49] Real-world second-line outcomes of NSCLC patients receiving first-line chemotherapy plus immunotherapy
    Russano, M.
    Cantini, L.
    B, A. P.
    George, R.
    Nunes, P.
    Tolba, K.
    Dutra, C.
    Chico, I.
    Cortellini, A.
    Pecci, F.
    Alessi, J. V.
    Ricciuti, B.
    Ramkissoon, S.
    Aerts, J. G.
    Agrawal, S.
    Saini, K. S.
    ANNALS OF ONCOLOGY, 2024, 35 : S854 - S854
  • [50] Outcome of advanced NSCLC patients harboring sensitizing EGFR mutations randomized to EGFR tyrosine kinase inhibitors or chemotherapy as first-line treatment: a meta-analysis
    Bria, E.
    Milella, M.
    Cuppone, F.
    Novello, S.
    Ceribelli, A.
    Vaccaro, V.
    Sperduti, I.
    Gelibter, A.
    Scagliotti, G. V.
    Cognetti, F.
    Giannarelli, D.
    ANNALS OF ONCOLOGY, 2011, 22 (10) : 2277 - 2285
12345